OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
April 27 2017 - 8:00AM
OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D.
has been appointed to its Board of Directors.
Dr. Nova is a life science industry veteran with extensive
experience building and leading novel genomics-based businesses.
She currently serves as president and chief executive officer of
Molecular Stethoscope, Inc., a newly formed molecular diagnostics
company. Most recently, she was senior vice president and general
manager of Illumina's oncology business unit. From 2000 to 2014,
Dr. Nova was a co-founder and director, president and chief
executive officer of Genoptix Medical Laboratory, which was
purchased by Novartis Pharmaceuticals Corporation for nearly $0.5
billion in 2011. She has also held senior positions with Nanogen,
Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova
currently serves on the board of directors for Arena
Pharmaceuticals and Veracyte and is vice chairman of the board of
directors for the newly formed Rady Pediatric Genomics and Systems
Medicine Institute, which is part of Rady Children's Hospital-San
Diego. Dr. Nova holds a B.S. degree in Biological Sciences from the
University of California, Irvine where she graduated with honors
and a Ph.D. in Biochemistry from the University of California,
Riverside.
“We are pleased to have Dr. Nova, a seasoned industry expert
with a portfolio of high caliber successes, join the OpGen Board,”
said Evan Jones, Chairman and CEO of OpGen. “Dr. Nova’s insights
and experience from having built and advised successful molecular
diagnostics companies will be invaluable as we continue to advance
the development of our Acuitas Rapid Test and Acuitas Lighthouse
Knowledgebase to combat the rise of multidrug-resistant organisms
in our hospitals and health systems.”
About OpGen OpGen, Inc. is harnessing
the power of informatics and genomic analysis to provide complete
solutions for patient, hospital and network-wide infection
prevention and treatment. Learn more at www.opgen.com and
follow OpGen on Twitter and LinkedIn.
Contact:
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-591-3443
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Apr 2024 to May 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From May 2023 to May 2024